Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma

NCT01701232 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT01701232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01701232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
January 31, 2017
Enrollment
174 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

follicular non-hodgkin's lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma